Answers are grounded in this paper and cite their sources.
Interview with Senator Orrin Hatch on the regulation of follow-on biopharmaceuticals. (06:07)Download Biopharmaceutical products, with U.S. sales in 2006 amounting to about $40.3 billion, are increasingly central to the treatment of major health problems affecting Americans.1 Since modern biopharmaceuticals date back to the 1980s, the first generation of such drugs has begun to lose patent protection (see table). In other parts of the world, governments have crafted regulations defining the terms of competition from “imitator,” or generic, products. Many analysts have expressed concern that without new U.S. regulations, patent expirations may not be accompanied by the introduction of competing, lower-cost biologic agents — or that imitator products might be approved without sufficient . . .
No takes yet. Share an insight, caveat, or question.
Richard G. Frank (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: